Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Biotechnology

Healthcare
$19.17 -1.71%

-$0.22 today

Market cap
$676.80M
Beta
1.08
P/E (TTM)
-36.5
EPS (TTM)
-$0.24
52W Low $7.59High $14.24

Volume 0.00M

Average 0.00M

Income Statement

Follow revenue through to earnings.

Revenue

$44.64M

FY 2025 · Annual

-6.1% YoY

Operating Income

-$6.35M

FY 2025 · Annual

Net Income

-$9.74M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.54M21.25M47.54M44.64M
Cost of Revenue086K1.26M3.18M3.76M
Gross Profit01.45M19.99M44.35M40.88M
Gross Margin—94.4%94.1%93.3%91.6%
Research & Development4.98M3.53M56K307K254.38K
Selling, General & Admin12.24M20.51M32.71M41.48M46.91M
Operating Expenses17.22M24.04M32.76M41.79M47.22M
Depreciation & Amortization17.22M149K287K800K103K
EBITDA(17.19M)(22.74M)(12.65M)4.8M(7.45M)
EBITDA Margin—-1481.2%-59.5%10.1%-16.7%
Operating Income(17.22M)(22.59M)(12.77M)2.57M(6.35M)
Operating Margin—-1471.6%-60.1%5.4%-14.2%
Interest Income54K195K441K1.68M800.78K
Interest Expense126K978K3.39M4.07M2.18M
Other Income / Expenses(123K)(1.13M)(3.27M)(2.64M)(3.29M)
Income Before Tax(17.35M)(23.71M)(16.05M)(71K)(9.64M)
Pre-Tax Margin—-1544.9%-75.5%-0.1%-21.6%
Income Tax Expense110K147K0365K106K
Net Income(17.46M)(23.86M)(16.05M)(436K)(9.74M)
Net Margin—-1554.5%-75.5%-0.9%-21.8%
EPS (Basic)(0.67)(0.91)(0.60)(0.02)(0.34)
EPS (Diluted)(0.67)(0.91)(0.60)(0.02)(0.34)
Weighted Avg Shares25.89M26.28M26.57M21.8M28.58M
Weighted Avg Shares (Diluted)26.01M26.28M26.57M27.3M28.58M

FRX.TO Earnings Waterfall · TTM

TSX:FRX.TO · Revenue to Net Income

Key Ratios

EPS$-0.30
Gross Margin92.0%
Net Margin-18.4%
P/E Ratio31.2
P/S Ratio18.9

Analysis

$51.2M of revenue converted into -$8.8M of net income for the selected period. Gross margin is 92.0% and net margin is -18.4%, showing how much revenue survives after costs and taxes. EPS is $-0.30, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

No filings found.

How much revenue does FRX.TO generate?

Fennec Pharmaceuticals Inc. (FRX.TO) reported $44.64M of revenue in fiscal 2025.

Is FRX.TO profitable?

Fennec Pharmaceuticals Inc. (FRX.TO) reported -$9.74M of net income, with a net margin of -21.8%.